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receiving cyclosporine/MMF (Nash et al, BBMT 2005), children have
signiﬁcantly higher MMF clearance rates (1.2 vs 0.54 L/kg/h). MMF
doses  3-fold higher than those used in pediatric SOT recipients
were required to achieve AUC0-630-60 mg  h/L. Short T1/2 and
rapid clearance of MMF in pediatric AlloSCT pts may be related to a
lack of enterohepatic recycling and enhanced UDP-glucuronosyl-
transferase activity.
Table 1. Age-related IV MMF PK on Day 14.
Age
Group
Cmax
(mg/L)
Tmax
(h)
Total
MPA
trough
(mg/L)
Mean
AUC0-6
(mg  h/L)
T1/2
(h)
Vss
(L/kg)
CL
(L/kg/h)
< 6
y.o.
(n8) 13.8 1.9 1.2 37.1 1.7 2.1 1.4
6-12
y.o.
(n8) 14.8 2.0 0.4 35.8 0.9 1.4 1.3
12-16
y.o.
(n7) 25.2 1.6 1.1 45.8 1.3 1.2 0.8
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CHARACTERISTICS OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN
BRAZILIAN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTS: A
FIVE-YEAR RETROSPECTIVE ANALYSIS
Bouzas, L.F.S.1, Moreira, M.C.P.1, Tavares, R.d.C.B.1, Lerner, D.1,
Azevedo, A.M.1, Mattos, M.1, Horn, P.1, Collares, M.1, Mellin, S.1
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Chronic graft-versus-host disease (cGVHD) is the leading cause
of non-relapse morbidity and mortality in the post-transplantation
period. Incidence rates and clinical characteristics have been
changing considerably in recent years, following increases in the
use of new sources of stem cells and donor/recipient age and the
introduction of new modalities of conditioning regimens. Inci-
dence rates reported in the literature have ranged from 20 to 70%,
being lower in the pediatric population and in recipients of cord
blood grafts. Use of donor lymphocyte infusions as a strategy to
control minimal residual disease or treat relapse is also a risk factor
for cGVHD. Among 95 patients analyzed, 29 (30.5%) were fe-
males. Median age was 35 years (18-64). Eighty seven patients had
hematologic malignancies (91.5%). The conditioning regimen was
myeloablative in 79 (83%). Bone marrow was used in 74 (78%) and
peripheral blood in 21 (22%). Prophylaxis of GVHD was done
with cyclosporine and methotrexate in 88 (92.5%). Sixty six
(69.5%) patients had acute GVHD before cGVHD. The median
time for the ﬁrst manifestation of cGVHD was 132 days (33-1499).
The installation of cGVHD was progressive in 37 (49%). Extensive
disease was present in 42 (56%). Eosinophilia (500/ul) was found
in 12 (16.5%). Lymphopenia (500/ul) was present in 19 (25%).
Thrombocytopenia ( 100,000/ul) was seen in 32 (41.5%). The
ﬁndings in our series are in accordance with the clinical proﬁle
usually reported in the literature. Because of its high morbidity and
mortality, the need for early detection of cGVHD can not be
overstated. Systematic, prospective evaluation of patients at risk for
this complication can contribute to better understanding of the
disease, and possibly, better control of the complications and im-
pact of advanced cGVHD in quality of life and survival expectancy.
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Accurate prediction of the onset and severity of GvHD and
treatment-related mortality (TRM) can improve outcomes
through optimized donor selection and GvHD prophylaxis. Cur-
rent assessments are typically made after bone marrow transplan-
tation (BMT), and often require inherently unreliable qualitative
measures. The persistence of host antigen presenting cells, partic-
ularly dendritic cells (DC) has been implicated in the onset of
GvHD, and a recent data suggests that extracorporeal photophere-
sis (ECP) can prevent GvHD after allogeneic BMT. We examined
blood from 32 ECP-treated patients to identify cell surface mark-
ers that might predict GvHD and TRM. Samples were drawn
immediately prior to ECP (at baseline) and immediately after ECP,
but prior to myeloablative conditioning, then assayed by ﬂow
cytometry. Cytometry data were grouped and modeled to assess
their predictive accuracy alone or in combination with clinical
laboratory values. Logistic regression showed that speciﬁc DC
subsets present prior to myeloablation were the best predictors of
outcomes. The likelihood of grade II-IV GvHD (aGvHD) in-
creases when baseline lin- HLA-DR CD11c myeloid cells make
up a smaller proportion of circulating mononuclear cells with a
predictive accuracy, reﬂected in the area under the receiver-oper-
ator curve (ROC) of 0.83. The best predictive model for TRM was
a lower absolute abundance of circulating lin- HLA-DR CD123
plasmacytoid DC at baseline (ROC0.86). No additional predic-
tive power arose with respect to aGvHD or TRM after including
laboratory values. Models that combined certain clinical laboratory
results and demographic factors also predicted these clinical out-
comes, and offer a possible alternative to complex cytometric
assays. The best such model included baseline measurements of
BUN/Creatinine ratio, serum albumin, and the match/relatedness
of the graft donor and recipient (ROC0.82, n59) for TRM,
while baseline neutrophil counts were most predictive of aGvHD
(ROC0.69, n60).
In summary, we have identiﬁed biomarkers that, at least in
patients receiving ECP, are present before conditioning and can
predict outcomes. Although this study does not address the impact
of ECP on antigen presenting cells directly, the DC proﬁles de-
scribed here highlight the potential role of ECP in modulating
DC, and thereby decreasing the risks associated with BMT. These
results encourage larger studies with non-ECP control populations
to directly address this issue.
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STEM CELL TRANSPLANT (HSCT)
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We report our long-term results using extracorporeal photo-
pheresis (ECP) for the treatment of chronic graft-versus-host dis-
ease (cGvHD). Between 2002 and 2005, 21 patients with steroid-
refractory or -intolerant cGvHD received ECP for a median
duration of 10.8 (range 1.3-58.8) months (Table). HSCT types
were 14 HLA-matched related donor (MRD), 6 HLA-matched
unrelated donor (MUD) and 1 HLA-mismatched unrelated cord
blood donor. Standard GvHD prophylaxis included a calcineurin
inhibitor with methotrexate (18), or methylprednisolone (2) or
both (1). Two (9.5%), 11 (52.4%) and 8 (38.1%) cases had mild,
moderate and severe cGvHD by CIBMTR criteria. Among the 19
patients with adequate follow-up (6 months post ECP initiation),
the sustained overall and complete response (OR and CR) rates
were 84.2 % (16/19) and 42.1% (8/19) with the maximum response
occurring at the median time of 1.8 (0.6-3.5) months from ECP
initiation. OR and CR rates by CIBMTR severity grading were
50% and 50% in the mild group, 45.4% and 36.4% in moderate
group, and 62.5% and 37.5% in severe group. Steroid-sparing
(steroid discontinuation or requiring adrenal doses only) was
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